These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
125 related articles for article (PubMed ID: 11808098)
1. [Digestive diseases and health economics]. Kobayashi Y Nihon Shokakibyo Gakkai Zasshi; 2001 Dec; 98(12):1335-40. PubMed ID: 11808098 [No Abstract] [Full Text] [Related]
2. Economics of cancer screening: total costs and benefits in economic terms. Pedersen KM Eur J Cancer; 1994; 30A(6):879-84. PubMed ID: 7917552 [No Abstract] [Full Text] [Related]
3. [Pharmacoeconomic analysis of treatment of certain diseases of the digestive system]. Parfenov AI; Vasil'ev IuV; Il'chenko AA; Guseĭn-Zade MG; Kniazev OV; Ruchkina IN; Efremov LI; Orlova IuN; Bystrovskaia EV; Masharova AA; Li IA; Deliukina OV; Kozhurina TS; Lazebnik LB Eksp Klin Gastroenterol; 2011; (2):97-105. PubMed ID: 21560648 [TBL] [Abstract][Full Text] [Related]
4. The necessity of accurate costs. Hankins S Am J Prev Med; 2009 Sep; 37(3):258-9. PubMed ID: 19666163 [No Abstract] [Full Text] [Related]
5. Cost-effectiveness of screening for HIV in primary care: a health economics modelling analysis. Baggaley RF; Irvine MA; Leber W; Cambiano V; Figueroa J; McMullen H; Anderson J; Santos AC; Terris-Prestholt F; Miners A; Hollingsworth TD; Griffiths CJ Lancet HIV; 2017 Oct; 4(10):e465-e474. PubMed ID: 28768604 [TBL] [Abstract][Full Text] [Related]
6. Cost-Effectiveness of Cancer Screening: Health and Costs in Life Years Gained. Ratushnyak S; Hoogendoorn M; van Baal PHM Am J Prev Med; 2019 Dec; 57(6):792-799. PubMed ID: 31753260 [TBL] [Abstract][Full Text] [Related]
7. Ensuring quality care for patients with digestive diseases. Brazer S Gastrointest Endosc; 1996 Aug; 44(2):204-7. PubMed ID: 8858334 [No Abstract] [Full Text] [Related]
9. Screening for colorectal cancer: what are the costs? Weller D; Moss J; Hiller J; Thomas D; Edwards J Int J Technol Assess Health Care; 1995; 11(1):26-39. PubMed ID: 7706012 [TBL] [Abstract][Full Text] [Related]
10. Economic impact of digestive, nutritional and oral diseases in Canada. Fedorak RN Can J Gastroenterol; 2000 Jan; 14(1):13-4. PubMed ID: 10655020 [No Abstract] [Full Text] [Related]
11. [Pharmacoeconomic aspects of the use of proton pump inhibitors]. Lazebnik LB; Masharova AA; Guseĭnzade MG Eksp Klin Gastroenterol; 2006; (4):67-72. PubMed ID: 17269427 [No Abstract] [Full Text] [Related]
12. The economics of prostate cancer screening. Benoit RM; Naslund MJ Oncology (Williston Park); 1997 Oct; 11(10):1533-43; discussion 1543, 1547-8. PubMed ID: 9348558 [TBL] [Abstract][Full Text] [Related]
13. [Pharmacoeconomics: the basic concepts and their application to digestive medicine]. Díaz de Rojas F Gastroenterol Hepatol; 1997 Feb; 20(2):68-77. PubMed ID: 9072207 [No Abstract] [Full Text] [Related]
14. Burden of digestive diseases in the United States part I: overall and upper gastrointestinal diseases. Everhart JE; Ruhl CE Gastroenterology; 2009 Feb; 136(2):376-86. PubMed ID: 19124023 [No Abstract] [Full Text] [Related]
15. Cost-utility analysis of orthoptic screening in kindergarten: a Markov model based on data from Germany. König HH; Barry JC Pediatrics; 2004 Feb; 113(2):e95-108. PubMed ID: 14754978 [TBL] [Abstract][Full Text] [Related]
16. Effect of screening for cancer in the Nordic countries on deaths, cost and quality of life up to the year 2017. Hristova L; Hakama M Acta Oncol; 1997; 36 Suppl 9():1-60. PubMed ID: 9143316 [TBL] [Abstract][Full Text] [Related]